Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Qin, Qiaojing ^a   Niu, Jianying ^a   Wang, Zhaoxia ^b   Xu, Wangjie ^b   Qiao, Zhongdong ^b   Gu, Yong ^a,c  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetes; Heparanase; Macrophage migration; PI3K AKT; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEPARANASE; PHOSPHATIDYLINOSITOL 3 KINASE; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BETA GLUCURONIDASE; IMMUNOGLOBULIN RECEPTOR; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MOTION; CELL SURVIVAL; DIABETIC ANGIOPATHY; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL MIGRATION ASSAYS, MACROPHAGE; CELL MOVEMENT; CELL SURVIVAL; DIABETIC ANGIOPATHIES; GLUCURONIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION; MACROPHAGES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84874195515     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-37     Document Type: Article

References (42)

1. Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, Thomas MC, Jandeleit-Dahm KA. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012, 61(8):2105-2113. 10.2337/db11-1546, 22698914.
2. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 2011, 8(1):35.
3. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 2011, 218(1):13-18. 10.1016/j.atherosclerosis.2011.06.029, 21763654.
4. Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, Maio RC, Legnaro M, Schembri L, Dentali F, Grandi AM, Guasti L. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Cardiovasc Diabetol 2012, 11:153. 10.1186/1475-2840-11-153, 3549933, 23259529.
5. Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, Webster DE, Miyazaki J, Kay TW, Slattery RM, Kaye DM, Drew BG, Kingwell BA, Fourlanos S, Groop PH, Harrison LC, Knip M, Forbes JM. Advanced glycation end products are direct modulators of β-cell function. Diabetes 2011, 60(10):2523-2532. 10.2337/db10-1033, 3178291, 21911745.
6. Zhong Y, Li J, Chen Y, Wang JJ, Ratan R, Zhang SX. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Muller cell-derived inflammatory cytokine production in diabetes. Diabetes 2012, 61(2):492-504. 10.2337/db11-0315, 3266398, 22228718.
7. Raposeiras-Roubín S, Rodiño-Janeiro BK, Paradela-Dobarro B, Grigorian-Shamagian L, García-Acuña JM, Aguiar-Souto P, Jacquet-Hervet M, Reino-Maceiras MV, Alvarez E, González-Juanatey JR. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. Cardiovasc Diabetol 2012, 11:102. 10.1186/1475-2840-11-102, 3489693, 22909322.
8. Peterson S, Liu J. Deciphering mode of action of heparanase using structurally defined oligosaccharides. J Biol Chem 2012, 287(41):34836-34843. 10.1074/jbc.M112.390161, 22893710.
9. Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I, Weinstein T. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One 2012, 7(9):e44076. 10.1371/journal.pone.0044076, 3441528, 23028487.
10. Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, Mandal TK, Clement C, McFerrin HE, Muniruzzaman S, Ireland SK, Hill JM. High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein e. PLoS One 2012, 7(12):e52152. 10.1371/journal.pone.0052152, 3526597, 23284911.
11. Purushothaman A, Babitz SK, Sanderson RD. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem 2012, 287(49):41288-41296. 10.1074/jbc.M112.391417, 23048032.
12. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, Doweck I, Vlodavsky I. Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem 2012, 287(9):6668-66678. 10.1074/jbc.M111.271346, 3307274, 22194600.
13. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, Sanderson RD. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115(12):2449-2457. 10.1182/blood-2009-07-234757, 2845901, 20097882.
14. Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, Platt JL, Gattuso P, Prinz RA. In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 2007, 282(4):2363-2373.
15. Osterholm C, Folkersen L, Lengquist M, Pontén F, Renné T, Li J, Hedin U. Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 2013, 226(1):67-73. 10.1016/j.atherosclerosis.2012.09.030, 23137827.
16. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, van der Vlag J, Vlodavsky I, Elkin M. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012, 61(1):208-216. 10.2337/db11-1024, 3237641, 22106160.
17. Baker AB, Chatzizisis YS, Beigel R, Jonas M, Stone BV, Coskun AU, Maynard C, Rogers C, Koskinas KC, Feldman CL, Stone PH, Edelman ER. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010, 213(2):436-442. 10.1016/j.atherosclerosis.2010.09.003, 3042136, 20950809.
18. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 2011, 1813(8):1475-1482. 10.1016/j.bbamcr.2011.05.004, 21600934.
19. An XF, Zhou L, Jiang PJ, Yan M, Huang YJ, Zhang SN, Niu YF, Ten SC, Yu JY. Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor. Mol Cell Biochem 2011, 354(1-2):47-55.
20. Rao G, Ding HG, Huang W, Le D, Maxhimer JB, Oosterhof A, van Kuppevelt T, Lum H, Lewis EJ, Reddy V, Prinz RA, Xu X. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia 2011, 54(6):1527-1538. 10.1007/s00125-011-2110-z, 21424539.
21. Li H, Peng W, Jian W, Li Y, Li Q, Li W, Xu Y. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol 2012, 11:65. 10.1186/1475-2840-11-65, 3461463, 22694757.
22. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol 2011, 10:12. 10.1186/1475-2840-10-12, 3041659, 21276212.
23. Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 2006, 147(5):2518-2525. 10.1210/en.2005-0519, 16455783.
24. Li Y, Liu S, Zhang Z, Xu Q, Xie F, Wang J, Ping S, Li C, Wang Z, Zhang M, Huang J, Chen D, Hu L, Li C. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One 2012, 7(4):e35016. 10.1371/journal.pone.0035016, 3322163, 22496883.
25. Soulis V, Thallas S, Youssef RE, Gilbert BG, McWilliam RP, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997, 40(6):619-628. 10.1007/s001250050725, 9222639.
26. Xu Y, Feng L, Wang S, Zhu Q, Lin J, Lou C, Xiang P, He B, Zheng Z, Tang D, Zuo G. Phytoestrogen calycosin-7-O-β-D-glucopyranoside ameliorates advanced glycation end products-induced HUVEC damage. J Cell Biochem 2011, 112(10):2953-2965. 10.1002/jcb.23212, 21647942.
27. Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, Vlodavsky I, Ilan N. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer 2008, 113(5):1004-1011. 10.1002/cncr.23680, 2625296, 18618498.
28. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009, 102(5):823-828.
29. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V, Petcherski S, Avniel-Polak S, Eitan A, Hammerman H, Aronson D, Axelman E, Ilan N, Nussbaum G, Vlodavsky I. Macrophage Activation by Heparanase Is Mediated by TLR-2 and TLR-4 and Associates With Plaque Progression. Arterioscler Thromb Vasc Biol 2013, 33(2):e56-e65. 10.1161/ATVBAHA.112.254961, 23162016.
30. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I, Ilan N. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 2009, 69(5):1758-1767. 10.1158/0008-5472.CAN-08-1837, 2650747, 19244131.
31. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007, 361(4):829-834. 10.1016/j.bbrc.2007.06.188, 2390716, 17689495.
32. Rubinfeld H, Cohen-Kaplan V, Nass D, Ilan N, Meisel S, Cohen ZR, Hadani M, Vlodavsky I, Shimon I. Heparanase is highly expressed and regulates proliferation in GH-secreting pituitary tumor cells. Endocrinology 2011, 152(12):4562-4570. 10.1210/en.2011-0273, 22009724.
33. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M, Lupo A. Heparanase and Syndecan-1 Interplay Orchestrates Fibroblast Growth Factor-2-induced Epithelial-Mesenchymal Transition in Renal Tubular Cells. J Biol Chem 2012, 287(2):1478-1488. 10.1074/jbc.M111.279836, 3256891, 22102278.
34. Boudot C, Saidak Z, Boulanouar AK, Petit L, Gouilleux F, Massy Z, Brazier M, Mentaverri R, Kamel S. Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells. Bone 2010, 46(5):1416-1423. 10.1016/j.bone.2010.01.383, 20149906.
35. Granado MH, Gangoiti P, Ouro A, Arana L, González M, Trueba M, Gómez-Muñoz A. Ceramide 1-phosphate (C1P) promotes cell migration Involvement of a specific C1P receptor. Cell Signal 2009, 21(3):405-412. 10.1016/j.cellsig.2008.11.003, 19041940.
36. Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar MG. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol 2008, 182(2):381-393. 10.1083/jcb.200712066, 2483528, 18663145.
37. Xu Y, Feng L, Wang S, Zhu Q, Zheng Z, Xiang P, He B, Tang D. Calycosin protects HUVECs from advanced glycation end products-induced macrophage infiltration. J Ethnopharmacol 2011, 137(1):359-370. 10.1016/j.jep.2011.05.041, 21669275.
38. Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, Shoji T, Mima Y, Motoyama K, Fukumoto S, Shioi A, Emoto M, Yamamoto Y, Yamamoto H, Nishizawa Y, Kurajoh M, Yamamoto T, Inaba M. Receptor for advanced glycation End products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of toll-like receptor 2. Diabetes 2013, 62(2):478-489. 10.2337/db11-1116, 23011593.
39. Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, Qu W, Quadri N, Ananthakrishnan R, Furmansky M, Rosario R, Song F, Rai V, Weinberg A, Friedman R, Ramasamy R, D'Agati V, Schmidt AM. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010, 59(8):2043-2054. 10.2337/db09-1766, 2911065, 20627935.
40. Milutinovic PS, Alcorn JF, Englert JM, Crum LT, Oury TD. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol 2012, 181(4):1215-1225. 10.1016/j.ajpath.2012.06.031, 3463633, 22889845.
41. Tang CH, Keng YT, Liu JF. HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells. Cancer Lett 2012, 322(1):98-106. 10.1016/j.canlet.2012.02.014, 22361176.
42. Rai V, Maldonado AY, Burz DS, Reverdatto S, Schmidt AM, Shekhtman A. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem 2012, 287(7):5133-5144. 10.1074/jbc.M111.277731, 3281598, 22194616.